Latest Breakdown,Hims & Hers announced March 9, 2026

The world of weight loss and metabolic health has been significantly influenced by the advent of semaglutide, a potent GLP-1 medication. For many, the journey to access these treatments has led them to telehealth platforms like Hims & Hers. However, the Hims & Hers semaglutide story is one of innovation, evolving strategies, and significant regulatory attention. This article delves into the complexities of Hims & Hers semaglutide, exploring its offerings, the legal and regulatory challenges it has faced, and its current standing in the market.

Understanding Semaglutide and its Role

Semaglutide is a GLP-1 medication that mimics a naturally occurring hormone. It plays a crucial role in regulating appetite and blood sugar levels. Primarily known for its effectiveness in weight management for individuals with obesity or overweight with at least one weight-related condition, semaglutide is available under brand names such as Wegovy (for weight loss) and Ozempic (for type 2 diabetes). The Wegovy brand-name semaglutide medication has become a focal point for many seeking effective weight loss solutions.

Hims & Hers' Evolving Strategy with Semaglutide

Initially, Hims & Hers sought to provide accessible semaglutide options, including a compounded version. This strategy aimed to offer an alternative, particularly when brand-name medications faced shortages. Hims & Hers announced the launch of a compounded semaglutide pill designed for weight loss, positioning it as an alternative to Novo Nordisk's offerings. The company even highlighted its success in selling semaglutide, especially during periods of high demand. For some users, Hims & Hers semaglutide has yielded positive results, with individuals reporting significant weight loss and appetite curbing. One user shared, "It was not a scam for me. I used a 3 months supply which I stretched out to about 16-17 weeks and lost about 40 lbs from September 2024 to January 2025." Another testimonial noted, "It has lowered his a1c greatly and is the only thing that has curbed his big appetite. It greatly causes you to not be hungry."

However, this approach led to considerable scrutiny. Hims & Hers faced legal threats and regulatory pressure. Notably, Novo Nordisk challenged Hims & Hers over its unapproved semaglutide offerings. The company has since shifted its strategy. Hims & Hers announced a strategic shift for its US weight loss offerings, entering into an agreement with Novo Nordisk. As part of this new arrangement, Hims & Hers will no longer advertise its compounded semaglutide options on its platform or in its marketing. This also means Hims & Hers will no longer sell compounded versions of semaglutide. The company has also withdrawn its $49 compounded semaglutide pill after pressure from top U.S. health officials at the FDA and HHS.

Regulatory Hurdles and Legal Challenges

The primary issue surrounding Hims & Hers' previous semaglutide offerings revolved around compounded drugs. Hims' compounded drug is not FDA-approved and has not undergone the rigorous clinical trials required to prove efficacy and safety in the same way as FDA-approved medications. This lack of FDA approval led to significant concerns from regulatory bodies and the manufacturer of the original drugs.

A significant development was the lawsuit filed against Hims & Hers, alleging that their compounded semaglutide GLP-1 does not contain the same active ingredients as Ozempic and Wegovy. This class action lawsuit highlights the critical difference between FDA-approved medications and compounded versions, where the exact composition can vary.

Furthermore, Hims & Hers has been under scrutiny for promoting compounded weight-loss drugs without clear FDA approval or comprehensive information on potential side effects. The company's Super Bowl ad, which touted its compounded semaglutide, drew particular attention and controversy.

The Current Landscape and Future Outlook

Following these developments, Hims & Hers has entered into a new agreement with Novo Nordisk, announced on March 9, 2026. This partnership signifies a major shift, with Hims & Hers now focusing on offering Novo Nordisk's FDA-approved semaglutide medications. This includes Ozempic® (semaglutide 0.5 mg, 1 mg, and 2 mg injections) and Wegovy®. This move aims to resolve the previous disputes and align Hims & Hers with regulatory standards.

For individuals seeking semaglutide treatment, Hims & Hers now offers a pathway to obtain FDA-approved options. The platform emphasizes personalized weight loss care, doctor-backed treatment plans, and ongoing support, all prescribed online. For women, Hers